The gene products of Itgal and Itgb3 are targeted by, respectively, lifitegrast, approved to treat dry eye, and eptifibatide, which inhibits platelet aggregation and is approved to manage myocardial infarction. This evidence concerns the gene ITGAL and myocardial infarction.